- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05313451
Evaluation of the Effect of a Soluble Fiber Consumption on Immunity Response (NUTIVAC)
Evaluation of the Effect of a Soluble Fiber Consumption on the Immune Response Post-influenza Vaccination in Healthy Subjects Aged 50 to 70 Years
At European level, the European Food Safety Agency has recognized two claims relating to the effects of prebiotics on the gastrointestinal sphere and on the immune system. In subjects aged 45-63, it was shown that a pre- and post-vaccination inulin consumption of 8g/day significantly increased the titer of antibodies directed against the H3N2 viral strain. The increase in bifidobacteria in the faeces confirmed that this effect was related to prebiotic capacities. The effect of prebiotics and probiotics on the immune response to influenza virus vaccination has been studied in two systematic reviews and meta-analyses. The authors show that the consumption of prebiotic fibers such as FOS, GOS, inulin, was also effective on the H3N2 strain, as on the H1N1 and B strains (antibody titers of 19.5%, 20.0% and 13.6% higher, respectively, compared to placebo).
The soluble fiber under study is a resistant dextrin meeting the definition of a prebiotic fibre. The prebiotic properties have been demonstrated in humans in several studies for doses ranging from 10 to 20 g/day. Similarly, studies show that the effects on immune functions are favorably impacted by a consumption of 10 g/day for 8 weeks . These results confirm those of a preclinical study conducted in mini-pigs.
The main objective of these study is to demonstrate that these prebiotic properties could help stimulate the post-vaccination immune response, and more specifically the production of antibodies directed against seasonal influenza viruses (following vaccination), and modulate the pro- and anti-inflammatory responses.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Screened participants who met the eligibility criteria are randomized either in the control or test (soluble fiber) group.
They are asked to ingest placebo or test product at 15 g/d dosing for 60 days (2 months) . At the end of the first month (30 days) they get vaccinated against influenza virus. The effect of soluble fiber on immune response is assessed by the comparison of HI titration 30 days after vaccination between groups.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Florent HERPIN
- Phone Number: 0380680506
- Email: florent.herpin@groupecen.com
Study Locations
-
-
Bourgogne
-
Dijon, Bourgogne, France, 21000
- CEN Nutriment
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Main Inclusion Criteria:
- Subject with a body mass index (BMI) of 18.0-30.0 kg/m 2
- Subject with regular upper respiratory tract infections(nasopharyngitis, flu-like illness, flu, cold...)
- Subject accepting the anti-influenza virus vaccination
- Subject agreeing to maintain lifestyle and dietary habits over the study
Main Exclusion Criteria:
- Subject having had the flu during the current season
- Subject having presented a viral or bacterial infection in the past 7 days prior to inclusion
- Subject with a known allergy to one of the compounds of products administered in the study or in accordance with indications of the vaccine
- Subject having presented manifestations of allergy during previous flu vaccinations
- Subject with ongoing gastrointestinal disease or chronic gastrointestinal disease (IBS, Crohn's disease, etc.)
- Suffering from diabetes, an autoimmune disease, a disease inflammation or a major or progressive pathology
- Pregnant women (negative urine pregnancy test for women of childbearing age), breastfeeding or planning a pregnancy in the coming months
- Subject who has already received the influenza vaccine for the current season
- Subject having received any vaccination during the last month prior to inclusion
- Subject who received antibiotic therapy within the last two month
- Taking any dietary supplements or enriched foods that are presented as having an action on immunity and/or on the intestinal sphere (prebiotics, probiotics, vitamins, plant extracts...) in the last month.
- Taking immunomodulatory or immunosuppressive drugs
- Taking any treatment that the investigator believes may interfere with investigation endpoints.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Soluble fiber
Participants ingest 15 g daily of the experimental product for 2 months and receive the influenza vaccine at the end of the first month.
|
15g/day during 2 months
|
Placebo Comparator: Placebo
Participants ingest 15 g daily of the placebo product for 2 months and receive the influenza vaccine at the end of the first month.
|
Maltodextrin 15g/day during 2 months
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from baseline HI titers at 2 months
Time Frame: at Month 1 (before influenza vaccination), at Month 2 (one month after influenza vaccination)
|
hemagglutination inhibition (HI) antibody titers after vaccination
|
at Month 1 (before influenza vaccination), at Month 2 (one month after influenza vaccination)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Intestinal Microbiota
Time Frame: at month 0, At month 1, at month 2
|
The microbiota is characterized using the Shotgun bacterial DNA analysis method on feces samples
|
at month 0, At month 1, at month 2
|
Inflammatory biomarker
Time Frame: at month 0, at month 1, at month 2
|
Interleukins
|
at month 0, at month 1, at month 2
|
Cytokin biomarker
Time Frame: at month 0, at month 1, at month 2
|
Tumour Necrosis Factor alpha cytokin
|
at month 0, at month 1, at month 2
|
Incidence of Treatment on hematologic blood parameters
Time Frame: at month 0, at month 1, at month 2
|
Complete blood count
|
at month 0, at month 1, at month 2
|
Incidence of Treatment on biochemical blood parameters
Time Frame: at month 0, at month 1, at month 2
|
Transaminases
|
at month 0, at month 1, at month 2
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 1699
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Immune Response
-
University of OxfordRecruiting
-
Inmunotek S.L.Not yet recruiting
-
Biosearch S.A.Completed
-
Mayo ClinicCompletedImmune ResponseUnited States
-
National Institute on Aging (NIA)Completed
-
Radboud University Medical CenterCompletedInnate Immune Response | Immune Tolerance
-
Gadjah Mada UniversityCompletedHumoral Immune ResponseIndonesia
-
Radboud University Medical CenterCompletedInnate Immune Response
-
Society for Applied StudiesNorwegian Institute of Public Health; Christian Medical College, Vellore, IndiaCompletedInnate Immune ResponseIndia
-
Assistance Publique - Hôpitaux de ParisInstitut National de la Santé Et de la Recherche Médicale, FranceRecruiting
Clinical Trials on Soluble fiber
-
Tufts UniversityRecruitingSarcopenia | Microbial Colonization | Dietary ExposureUnited States
-
Purdue UniversityTate and Lyle Ingredients Americas LLCCompleted
-
Phoenix Children's HospitalMayo Clinic; Northern Arizona University; Flinn FoundationCompleted
-
JeyaKumar HenryTate and Lyle Ingredients FranceCompletedObesity | Pre DiabetesSingapore
-
University of Illinois at Urbana-ChampaignTate and Lyle Ingredients Americas LLCRecruiting
-
Jinling Hospital, ChinaTerminated
-
University of MinnesotaTate and Lyle Ingredients FranceCompleted
-
Purdue UniversityTate & Lyle Health & Nutrition SciencesCompletedOsteoporosis, Postmenopausal
-
Mayo ClinicCompletedType 1 Diabetes